Download - Alzheimer’s Disease & Treatment - Open Access eBooksopenaccessebooks.com/alzheimers-disease-treatment/down... · 2019. 3. 15. · Alzheimer’s Disease & Treatment London J nuclei

Down Syndrome for A Better Understanding Alzheimer Disease

London J

Université Paris-Diderot, Sorbonne Paris Cité, BFA, UMR8251, CNRSF-72205, Paris, France

Email: [email protected]

Chapter 2

Alzheimer’s Disease &Treatment

1. Introduction

A) Alzheimer disease (AD)

AD is the most common of dementia and affect millions individuals worldwhilecharacterizedmainlybylossofmemoryandcognitivedeclinebutalsobysensoryandmotorimpairments.MostADcasesaresporadic(SAD98%ofcases)atagemorethan60yearsbutsomehaveageneticinheritance(2%around)atageearlierthan60yearsandsomeateven40years[1].TheautosomaldominantAD(ADAD)arerelatedtomutationsonpresenilin1(PSEN1 ; chromosome14;18-50%ADADcases)andpresenilin2(PSEN2 ;chromosome1; <5% ADADcases)andonAmyloidPrecusorProtein(APP ;chromosome21;10-15%ADADcases).

Atthebiochemicallevel,SADorADADischaracterizedbyextracellulardepositsofsynaptotoxicβ-amyloid(Aβ)peptides,mainlyAβ40andAβ42peptides infibrilsstructuresformingamyloidsenileplaques(SPs)andbyintraneuronalneurofibrillarytanglesofanormallyphosphorylatedTauproteins(NTFs)[2,3].

Theseneuronalchanges induceprogressiveneuronalandsynapticdeficits leading tomanydeficitincludingaprogressivecognitivedecline.Theyarepresentmayyearsbeforetheapparitionoftheearlyclinicalsymptomsandthiswindowofmorethan10yearsmayoffernotonlymethodsforearlydiagnosisbutalsoearlytreatmentsinthediseaseprocessbeforeitistoosevere.

TheSPsbeginaccordingtoBraakstagesmainlyintheneocortexforphase1,spreadingtotheallocortexandtheninphase3tothediencephalicenuclei,thestriatumandthecholinergic

2

www.openaccessebooks.com

Alzheimer’sDisease&TreatmentLo

ndon

J

nucleiof theforebrain,and inphase4and5 tootherbrainnucleiandcerebellum[4]. SPsaccumulationprecedebymanyyearsthefirstclinicalsymptomsofADbutsomeindividualsnever develop dementia despite the presence of SPs.Aβ peptides are present undermanyspeciesderivedfromtheclivagebyαandβsecretasesoftheAPPproteinderivedfromtheclivagebyβandγsecretasesoftheAPPproteinbutthemainspeciesareAβ40andAβ42; thesepeptidesundergoabnormalconfigurationswhichbyspreadingleadtoaggregatespresentinSPsmainlyduethehydrophobic25-35sequenceoftheAβ[5].

NFTs are present in cell bodies and apical dendrites and in abnormal neurites.Theneurofibrillary lesionsaremainlydue toaggregatesof the tauproteinwhich isabnormallyphosphorylatedinspecificsitesmainlyonthreonine212 (7-8molofphosphateinNTFsinsteadof2-3molincontroltauprotein[6]. HyperphosphorylatedTauproteintendstodissociatefrommicrotubules and thus induces axonal impairment.NTFs develop in the brain through sixBraakstagesstartingassilentinthetransenthorinalstagethentothethelimbicstagefortheincipientADandattheneocorticalstageforfullAD[7].MoreovertauhyperphosphorylationcanbeinducedbyAbetasolubledimers[8].

BesidesSPsandNTFs,neurotrophinssuchasBDNF(Brain-derivedneurotrophicfactor)andmonoaminessuchas serotonin (5-HT:5-hydroxytryptamine)are involved inADsincetheyregulatecooperativelysomeaspectsofneurogenesis,neuralplasticityandsurvivalduringaginginordertoallowthebraintorespondtoenvironmentaldemandswhichmaybeverydetrimenta.ManymonaminesarmodifiedinindivualswithAdandinmicemodellingAD[9].InAD,BDNFisdecreasedinthehippocampusandtheAβ42peptidemightcompromiseBDNFbothproductionandsignaling,leadingtoneuronaldegeneration[10].Reduced5-HTlevelsisoneofthemarkersofacceleratingcognitivedeclineinAD [11].OthermonoaminesDA,NAarealsoreducedincertainbrainareas(frontalandtemporalcortex,hippocampus)frominvidualswithADbutalsoinvariousbrainareasfromtheAPP/PS1mousemodelthatdevelopcerebralamyloidosis[12].Manypatientswithmildcognitiveimpairment(MCI)displaysomeoftheearlyclinicalsymptomsofAD.AmongthemsomewillbeatriskfordeveloppingADandsomewillnot.

B) Down syndrome (DS)

DSissofarconsideredasthemajorgeneticcauseofintellectualdisability.Downsyndrome(DS)isageneticdisorderthatresultsfromthetriplicationofentireorpartofchromosome21(Chr21)andoccursin1every1000/1500livebirthswithoutfamilyinheritance.IndividualswithDSarenotcharacterizedbyonesymptombutpresentseveralpathologicalphenotypeswhichtheaccumulationoftheminducestheso-calledDSphenotypewhichishighlyvariableamong individuals andduring aging [13]. Life expectancy in theDSpopulation is shortercomparedtonon-DSindividuals,butimprovementsinmedicalcareanddrugtreatmentshave

3

Alzheimer’sDisease&Treatment

significantlycontributedtoamelioratethelifequalityofthispopulationwhichnowapproaches65-70yearsandthusmaybeconcernedwithADasthegeneralpopulation.

Although the increased dosage of Chr21 genes might be one of the causes of thephenotypicalalterationsofDS,thepresenceoftrisomicgenesalsoaffectstheexpressionofdisomicgenes,which,inturn,maygainaberrantexpressionandcontributetosomeclinicalmanifestations. Brain development defects induces intellectual disabilities which affectlanguage,learning,memorybutalsomotor,sensoryandsleepdeficits.Moreoveritisreportedthat individuals with DS exhibit accelerating aging, behavioural abnormalities and earlyneurodegenerationwhichmaybeconsideredasmajorproblemsforthispopulation.

SeveralearlystudiessupportthelinkbetweentheDSphenotypeandanincreasedriskofADdevelopment[14;15;16].TheincidenceofdementiaamongDSpatientsis10%intheagerange35–50,55%intheagerange50–60,andbecomes75%abovetheageof60years,butADneuroanatomopathologyispresentinvirtuallyalladultswithDSolderthan40years.Despitetheseubiquitousstigmates,theprevalenceofdementiaisvariablerangingfrom30-75%atage65andmostofthecasesofdementiainindividualswithDSoccuraround50-55years.Nevertheless,thereisaratherlargesubsetofagedpersonswithDSwhodonotdevelopclinicalsignsofdementiaatanyage.Moreoveritisreportedthatinpeculiarcases,onewomanof78yearsandonemanof65years, theabsenceof theAPPgene in triplicate leaves theindividualswithoutthebiochemicalhallmarksofADandconsequentlynodementiaalthoughtheypresenttherestoftheDSphenotype[17-18].ThisrarepatientsconfirmthecrucialroleofAPPintheneuropathologicalandclinicalfindingsofADinindividualswithDS.However,althoughplaqueshavebeendetectedinyoungDSautopsysamples,andeveninsomefetalsamples,itisonlyinlatemiddleagethatpeoplewithDSdevelopADpathology[13;19]. Thesenileplaques aremainlydue to the abnormalmetabolismof theAPPprotein thegeneofwhichisonchromosome21andtheNTFareduetotheabnormalphosphorylationoftheTauproteinwhichmightbepartiallyduetosomechromosome21phosphatasesgenesandalsotosomesAPPαdimers[8].

In thefirst study to comprehensively characterizeDS sampleswith andwithoutADdiagnosisinport-mortembrainsamplesandintheCSF,evidentserotoninergicandnoradrenergicdeficitswerefoundinDSADversusearlyADinvidualsandtoalesserextentinDSversushealthycontrols[20].

AlthoughtheclinicalfeaturesandespeciallythetimecoursemightbedifferentinADinthegeneralpopulationandinindividualswithDS,thebiochemistryandpathologyofADinpeoplewithDSandinthetypicalpopulationareessentiallyidentical,thecurrent«amyloidcascadehypothesis»isbelievedtoapplytobothpopulations.Thus,thepopulationwithDSrepresentthebesthumanmodeltoapproachADfeaturesseveraldecadesbeforetheirreverible

4


dementiaoccurs.

2. Common Features between Individuals with DS and AD

TheageofonsetofdementiainindividualswithDSismuchearlier(35%attheageof60years)thantheinSAD(70-80)butissimilar(under60)totheautosomaldominantAD(ADAD)[1].

ThusADinDSindividualsconstituethelargerhumangroupwitharatherhomogeneousgeneticbackgroundtostudythemolecularpathwaysleadinginsomecasestodementia(DSAD)andthusallowingawindowtotestearlymarkersandbetterunderstandingthecourseofthisADdevastingdisease.

Although, thedefinitivediagnosisforADinthegeneralpopulationisoftengivenpostmortembybrainexamination,manyscalesofevaluationofthecognitivedeteriorationarenowused.UnlikefamilialAD,dementiainindividualswithDSisstillnotwelldescribedalthoughitaccountsforthemajorityofgeneticADcases.ThescalesusedforADevaluationsarenotgoodenoughforeapopulationlikeDSthathasasatbaselinesomecognitive impairmentsespeciallyincomprehension,memoryandlanguage.Nevertheless,theCAMDEX–DShasbeenvalidatedasareliabletoolforassessingclinicaldementiainpeoplewithDS[21],theRapidAssessmentofcognitivefunctioninDownsyndrome(RADD)[22] andthenovelBehavioralandPsychologicalSymptomsofDementia inDownSyndrome(BPSD-DS)are reported in[23], which in combination with an amyloid PET scan should increase the confidence ofdementiaofAlzheimer’stypeinDS.AgoodpresentationofthesimilaritiesanddifferencesbetweenclinicalpresentationsinDS,AD(orSAD)andADADalsonamedFADisgivenintheupdatedreviewparZisandStrydominwhichtheyreportalsothecomparisonofDSandADforbiomarkers[24].

2.1. Aβ peptides

Briefley, in the plasmaAβ40 andAβ42 levels are higher in individualswithDS; inDSAD,Aβ42tendstoincreasewhileAβ40decreasethustheratioAβ42/Aβ40hasnotthesametimecoursetoevaluatedementiaasinAD.InCSF,AβlevelshavebeenshowntoincreaseinchildhoodandthendecreasewhenSPsstarttodepositsimilarlytowhatisobservedinAD[19].

PositronEmissionTomographyimaging(PETscan)withligandssuchas[11C]-Pittsburghcompound–B(PIB)enables«in vivo »quantificationandlocalizationoffibrillarAβdepositsandalsotangles [25].

HigherPIBbindinglevelsincorticalandsubcorticalregionsoftheDSbrainwereobservedinparticipantswithhigherage,lowercognitiveperformanceonneuropsychologicalassessment,

5


andinthosewithadiagnosisofdementia[26,27,28].IntheirworkbyPETandvolumetricRMN[29]:they concludethatresultsfrompopulationswithamyloidoverproduction(DSandADAD) compared to the general populationmaybe generalizable because all populationsaccumulatethesameamyloidaggregatesandexperiencethesameoveralltemporalprogressionofADinwhichamyloidaccumulationprecedesneurodegenerationanddementia.

Increasedglobalamyloid-βwas related todecline inverbalepisodicmemory,visualepisodicmemory,executivefunctioning,andfinemotorprocessingspeed.ParticipantswhowereconsistentlyPiB+demonstratedworseningofepisodicmemory[30]. Othermodalitiesarenowdeveloppedsuchasdiffusiontensororretinalimagingtoimproveearlydiagnostic[31].

2.2. Tau

Microtubule-associated-protein tau is hyperphosphorylated and abnormallyphophorylatedinADandaggregatesinpairedhelicalfilaments(PHFs)inNTFs.Thepretanglestate, the intraneuonal tangles and the extyraneurocellular NTFs can be differentiated byspecifictoparticularTauepitopes[32].Ingeneral,NFTsfollowasimilardistributioninDSasinAD,startinginentorhinalcortexandspreadingtohippocampusandlaterneocortex,butatahigherdensityinDScomparedtoADbrain.IntheplasmathetaulevelsarehigherinADgroupsthaninthegeneralpopulation.InindividualswithDStheselevelsarealsohighereveninnondementedones[19].

2.3. APOE alleles and AD risk factor

APOE is a hepatocerebral lipoprotein that regulates the transport and deposition ofcholesterol.Evidencesuggeststhatharboringoneorbothapolipoproteinε4alleles(APOε4)mayincreasetheriskforADduetotheapoEasanessentialcatalystoftheamyloidcascadeandasubsequentlossoffunction[33,34].

InheritanceofonecopyofthealleleincreasesADriskfour-foldwhileinheritanceoftwocopiesincreasesriskten-foldinthegeneralpopulationTheAPOε4 allelealsoincreasesdementiariskinDS,albeittoalowerextentthaninAD.Atthebiochemicallevelthisincreasedriskisporbablyduetothepresenceofanamino-terminalapoEfragmentinboththefrontalcortexandhippocampusoftheDS-ADbrain[35].

2.4. Vascular pathology

VascularpathologyiscommoninthesusceptibiltytoADinthegeneralpopulation.Thecontributionofvascularpathologytodementiamayplayasimilarroleinageofonsetand/ortherateofprogressionofADinDS(DSAD)[36].Microbleeds(Bs)weremorefrequentinDScasesrelativetocontrolsbutpresenttoasimilarextentassporadicAD.Thisaligned

6


with cerebral amyloidangiopathy (CAA) scores,withmoreextensiveCAA inDS relativeto controls inbothbrain regions.CAAwas alsomore frequent inDSADcases relative tosporadicAD[37].Moreover,asreportedintherecentstudythatvascularormetabolicimagingmight provide earlier information regardingADpathogenesis [38]. In the hippocampus ofolderDSADindividuals,Myoinositol (MI) ishigher,Nacetylaspartate(NAA)is lowerandglutamate-glutaminecomplex (Glx) isunchangedwhencompared tonon-dementedpeoplewithDS.

2.5. Oxidative stress

Oxidativestress(OS)resultsfromaccumulationofoxidizedanddamagedmoleculeswhicharenotremovedbytheantioxidantdefensesystem(superoxidedismutases(SOD1,2and3),glutathioneperoxidase(GPx),catalaseetc)andthuscandamagevariouscellularandextracellularcomponents.ThechronicSOD1overexpressioninallcellsthatcharacterizesthetrisomy21 subjects and the consequent over-generationof endogenoushydrogenperoxideapparentlyisnotadequatelycompensatedbytherelativelymodestupregulationofcatalaseandGPx.Therefore,thischronicimbalancebetweenthelevelsofbothimportantantioxidantenzymes(SOD/CAT+GPX)andtheircorrespondingsubstratesinducingthegenerationofthemostdeleterioushydroxylradical(HO.),mightbethebasisforDSdisturbances.BiomarkersofoxidativestressaresignificantlyelevatedinDS[39].Theanti-oxidantsystemisaffectedinDSandthisdefectisworstenedduringaging[40].TheSOD1hasbeenshowntobeelevatedin the neocortex and the hippocampus of individualswithDS orAD [41]. Indeed loss ofantioxidantenzymesandanincreasedinproteinmodificationhavebeenreportedinAD[42,43].

2.6. Mitochondria

Alteredmetabolism ofAPPmight be related tomitochondrial dysfunction [44] andmutationsinmitochondrialDNAhavebeenrelatedtoADchangesinthegeneralpopulationaswellasintheDSone[45].

Several studies have shown that alterations of mitochondrial structure and functionassociatedwithan impairmentof reactiveoxygenspecies(ROS)homeostasisarecriticallylinkedtoDSpathogenesis.Deficitsinenergymetabolismduetomitochondrialdysfunctionsnegativelyaffectneuronalfunction,survivalandcentralnervoussystem(CNS)developmentwhichrequiresATPandoccurasanearlyeventinintellectualdisability-linkeddiseasesandseveralformsofdementialikeAD[46].OverexpressionofAPPmaypromotemitochondrialdysfunctioninDSindependentofaberrantAβdeposition.

ArecentreviewgivesasurveyoftheroleofmichondriaanditsimpairedfunctionsinrelationtooxidativestressbothinDSandAD[47].

7


2.7. mTOR Pathway

mTOR influencesAβdepositionand tauaggregationand thus is associatedwith thepathogenesis and progression ofAD and similarly in DS [28]. Briefly mTOR activationaffectstheregulationofAβgeneration/clearanceandtau-phosphorylationbyinhibitionoftheautophagyandbyinteractionwithseveralkeysignalingpathways,includingPI3K/Akt,GSK-3β,AMPKandinsulin/IGF.InhibitingmTORactivationforthetreatmentandpreventionofADandAD-likedementia inDShasbeenpointedbutmuchworkneed tobedonebeforegoingtoatrial[28].

2.8. Endosomes

IntracellularAβislocalizedtoendosomeswhichareresponsiblefortheturn-overandthedegradationoftheproteinswithincells.Earlyendosomesareamajorsiteofamyloidprecursorprotein(APP)processingandaconvergencepointformoleculesofpathologicrelevancetoAD. Neuronal endosome enlargement, reflecting altered endocytic function, is a disease-specificresponsethatdevelopsyearsbeforetheearlieststageofADandDS[48].Endosomalpathologycontributessignificantly toAβoverproductionandaccumulation insporadicADand inADassociatedwithDSandmaysignifyearlierdisease-relevantdisturbancesof thesignalingfunctionsofendosomes.OneofthemainpointregardingendosomesisthatlargeendosomesmightbeanhallmarkforearlydetectionforADinDSandalsoforADinthegeneralpopulation.More recently enlarged endosomes were detected in bloodmononuclear cellsandlymphoblastoidcell lines(LCLs)fromindividualswithADusingimmunofluorescenceandconfocalmicroscopyshowingthatitmaybeabiomarker[49].Thevolumesofenlargedendosomes correlate to [C11] PiB cortical index but not to the amyloid-beta, tau andphosphorylated tau levelsmeasured in thecerebrospinalfluid.Moreover theenlargmentofendosomesinDSisatleastpartiallyduetosynaptojaninpresentinthreecopies[50].

2.9. Mis-segregation in AD

In their analysis [51] of thousands of cells from 27AD and 13 control individualsshowedthatfibroblastsfromADpatientsweremorethantwiceaslikelytoexhibittrisomy21comparedtofibroblastsfromcontrolindividuals.Theincreasedfrequencyoftrisomy21cells infibroblasts fromADpatientswas significant and independentof age.Furthermore,thechromosomemis-segregationwasassociatedwithalltypesofAD,includingsporadicandfamilialADcarryingamutationineitherPS1orPS2.

3. Differences Between DS and AD Regarding Pathological Aging

3.1. Clinical aspects

IntheDSpopulation,theprevalenceofdementiaincreasesrapidlyaftertheageof30

8


yearsalthoughdataareverydifferentfromtheveryfewcohortsstudied.TheoverallprevalenceofdementiainadultswithDSisestimatedat6.8%withanincreasewithagefrom8.9%inindividualsupto49yearsto32.1%inindividualsfrom55to59yearsoldbutithasalsobeenreported higheras33%amongindividualswithDSaged30to39years,55%amongthoseaged40to59years,and77%forindividualsabovetheageof60years.Itshouldbepointoutthatindividualswhonowadaysreacholdagesarethosewhodidnothavecardiacabnormalitieswhichmostoftenwereletalwithoutcardiacsurgeryavailablesince30yearsindeveloppedcountries[19;29].ArecentstudyshowssomepredictionsaboutsurvivalofpeoplewithDSaccordingtotheoccurrenceofAD[52].

Bycomparison,theprevalenceofdementiainthegeneralpopulationisestimatedas4%below65years,15%between65and74years,43%between75and84years,and38%overtheageof85years[29].

3.2. Amyloid and tau aspects

Theearlystudyon42casesofDSunder40yearsdemonstratetheAβdepositionwithinthehippocampusandparahippocampalgyruspriortoNFTinneuronsordystrophicneuriteswithinSPs[53].MoreoverinthisstudyandothersitisreportedthatAβdepositioninchildhoodandteensmightbemorefrequentthanpreviouslyestimatedinDSandalsothaninthegeneralpopulation.Bothinfants,childrenandteenswithDSaccumulateintracellularAβpriortotheaccumulationofextracellularAβdeposits[54].

Aβ production from APP nonspecific proteolytic cleavage leads to heterogeneousAβ (includingAβ40/42/43) in a possible endosomal/lysosomal location [55]. There is anaccumulation of intracellularAβ within neurons in DS at a much earlier age than in thegeneralpopulation.MoreoverAβmeasuredbiochemicallyincreaseduringagingsuggestinganaccelerationphasetodiseasedevelopment[56].

Schupfandcolleaguesreported that increasing levelsofplasmaAβ40anddecreasedAβ42wereinDSgoodpredictorsofconversiontodementia [57].Indeed,adultswithDSwithdecreasingplasma42overtimewere5timesmorelikelytobecomedementedwithin4years.Similarly,inaseparateprospectivestudyon405personswithDS,thoseadultsinthehighestlevelsofplasmaAβ42andAβ40alsohad thehighest riskofdevelopingdementiaoveranaverage4.7yearperiodoftime[58].

PIBbindinginDS,firstappearinginstriatum,beganaroundage40andwasstronglyassociatedwithdementiaandcognitivedecline.Theabsenceofasubstantialtimelagbetweenamyloidaccumulationandcognitivedeclinecontrastsinsporadic/familialAD[27].ThestudybyPET imaging [59] has shown that inDSbrain,Aβbinds to (18F)florbetaben and thatthisbindingincreaseswithage. Increasedglobalamyloid-βwasrelatedtodeclineinverbal

9


episodicmemory,visualepisodicmemory,executivefunctioning,andfinemotorprocessingspeed.ParticipantswhowereconsistentlyPiB+demonstratedworseningofepisodicmemory [60].

Regardingβamyloidpeptides,itisinterestingtonotethatBACE-2,achromosome21proteinwhichactivatesBACE1,wasobservedonlyinneuronsofadultswithDSbutnotinyoungpeopleandinindividualswithAD.

FewstudieshavefocusedontauproteinsinthecourseofADinDSbutarecentoneshedanewlightonthisoldcontroverseaboutthefirsthallmarksinAD[61].

3.3. Other biochemical aspects

As in theADbrain, themajorityofproteinshavebeendemonstrated tobeoxidized(OS),thusthenotionthataberrantproteinoxidationinDSmaycontributetoADdevelopmentisrelevant.InDSbrain,despiteincreasedOSlevels,nochangesinHO-1proteinlevelshasbeen observed in young subjects, whereas increased levels characterize adultDS subjectsundergoingAD-likeneurodegeneration.Interestingly,increasedofHO-1inDS/ADsubjectsisnotcomparablewiththatobservedinADsubjects.Thisphenomenonseemslikelylinkedtothetrisomyofchromosome21BACH1gene,whichencodesforthenuclearrepressorofHO-1gene[62].IndeedHNEmodifiedproteinshavebeenshowninexcessinDSbrain [63].

AccumulatingevidencealsosuggeststhatimpairedironhomeostasisisanearlyeventinADprogressionbutalsoinDSAD[64].Irondyshomeostasisleadstoalossoffunctioninseveralenzymesrequiringironasacofactor,theformationoftoxicoxidativespecies,andtheelevatedproductionofbeta-amyloidproteins.DSmightrepresentaspecificcaseofgeneticallyencodedOS.Indeed,thereareanumberoftrisomicgenes,thatdirectlyorindirectlyaffectsROSlevels,eitherbycausingincreasedROSproductionordecreasingtheantioxidantresponse[65].ThemolecularmechanismslinkingirondysregulationtoneurodegenerationinDSarestillpoorlyunderstood.

4. Chromosome 21 Genes Involved Directly or Indirectly in AD

TheentiresequenceofhumanChromosome21isnowknownandthereare233codinggenes,299longnon-codinggenes(Ensemblrelease78)and29microRNAs(miRBaserelease21).AfterinvestigationwithSwiss-ProtandanalysiswithGeneOntologyAnnotation,the207proteinsfoundencodedonChr21: i) takepart in87differentbiologicalprocesses,and11proteinsareinvolvedinsignaltransduction;ii)have81differentmolecularfunctionsamongwhichDNAbindingandtranscriptionfactoractivityarethemostprevalentwith15proteins;iii)arelocalizedin26differentcellularcomponents,nucleusandtheplasmamembranewith19and15proteins,respectively,arethemostpredominantcellularlocalizations[66].

10


Somechromosome21genesmightbeimportanttobetterunderstanddirectlyAD.Moreoversomeofchromosome21genescanregulateothergenesandsignallingproteininvolvedinAD.Themostimportantchromosome21genesknownnowtobeinvolvedinADare:APP,BACE2,BACH1,DYR1A,ETS2,RCAN1,S100β, SOD1,SYNAPTOJANIN.These genes encodeproteinswhichhavebeenshowntobeimportantforsomeoftheDSphenotypeincludingtheAD[67].

APP •

ThegenecodingfortheAPPproteinisonchromosome21anditspromoterisregulatedbyEts-2ananothergeneofchromosome21whichisoverexpressedinDSexplainingatleastpartiallythefactthatAPPismorethan1.5expressedinDScellsandtissues.APPhasalreadybementionnedpreviouslyasthesourceoftheamyloidpeptideswhichduetotheirabnormalfoldingwillleadtoagregatesandlaterontofibrills[68].ButitshouldbealsopointoutthattheproteolyticcleavagebyαsecretasegivesthesAPPαextracellularfragmentwhichhasbeenshowntobebeneficialforsomecognitivefunctionsespeciallymemory,forneuriteoutgrowth,preventsAβgenerationandtauphosphorylation,counteracttheAβeffectsandfinallydisruptAPPdimers[69].ThesAPPαextracellularfragmentispresentatlowerlevelsinindividualswithADthanincontrols.Itspotentialbeneficialrolefromanombilicalcordsourcehasbeenrecentlyassayed inanimalmodels forADandshown tobemediatedbycomplementC1q [70].

BACE-2•

BACE-2 cleavesAPP,isincreasedinDSand thuscontributestoincreasedAβproduction[71.MoreoverBACE-2activatesBACE1,oneoftheproteolyticenzymeoftheamyloidcascade[72].

BACH1•

BACH1 is a basic leucine-zipper protein and the nuclear repressor of HO-1 gene.IncreasedBach1expressionlevelsareinvolved,overall,inrepressingtheinductionofHO-1in DS cases, thus reducing HO-1 overexpression in stress conditions as observed inAD.OverexpressionofBACH1isalsorelatedtooxidizedspecies[62].

CBS•

CBSlevelsinDSbrainsareapproximatelythreetimesgreaterthanthoseinthenormalindividuals andCBS is localized to astrocytes and those surrounding senileplaques in thebrainsofDSpatientswithAD[73].CBSisthemainenzymeproducingH2S.CBSactivityisreducedinADbrainsandthedecreaseinH2Smaybeinvolvedinsomeaspectsofthecognitivedecline inAD [74].Moreover, several experiments have shown in different rat ormurine

11


modelsofADthatH2Scouldbebeneficial[75].

TheCBSoverexpressioninducesmonoaminepathwaysalterationsinvariousbrainareasofCBStransgenicmiceaccordingtosexandage[76].ThusthesealterationsbyCBSover-expressionmightbeinvolvedinthedevelopmentalabnormalitiesincognitioninDSchildrenandthatmayleadtoADinDSadults.

DYRK1A•

TheDYRK1AgeneencodestheproteinDYRK1Awhichisaserine/threoninekinase.Dyrk1AisoverexpressedinSPsfromADindividualsandisakeymoleculebridgingβ-amyloidproductionandtauphosphorylationinAD[77].ItphosphorylatestauproteinmakingitabettersubstrateforGSK3βphosphorylation,andDYRK1Aphosphorylatesalternatesplicingfactorsleadingtoanincreaseratioof3R:4Rtau,whichisassociatedwithneurodegeneration;consistentwiththisfinding,thereisanincreaseinthenumberofDYRK1A-positiveand3R-positiveNFTsinmiddle-agedandolderDSbraincomparedtosporadicAD[78].OverexpressionofDYRK1AitatleastpartiallyresponsiblefortheexcessivesynapticinhibitioninpeoplewithDSwhichcanbereversesbothinindividualswithDS andinanimalmodelsbyinhibitingDYRK1Awithcatecholcompounds[79;80;81].MoreoverDYRK1Aoverexpressionmodulatesmonoaminesneurotransmitters in transgenicmicealteringboth the serotoninergicand thedopaminergicpathways[82].

ETS2•

Overexpression of ETS2 in DS may play a role in the pathogenesis of the brainabnormalities in DS and possiblyAD [83]. Degeneration of DS neurons was reduced bydominant-negativeETS2,suggestingthatincreasedETS2expressionpromotesDSneuronalapoptosis.Inthehumanbrain,ETS2expressionwasfoundinneuronsandastrocytes.StrongETS2 immunoreactivitywas observed in DS/AD and sporadicAD brains associatedwithdegenerativemarkerssuchasBax,intracellularAbeta,andhyperphosphorylatedtau[84].

RCAN1 •

RCAN1levelsareincreasedinthebrainofDSandADpatientsbutalsointhehumanbrainwithnormalaging[85]. RCAN1hasbeenimplicatedinseveralneuronalfunctionsincludinghippocampalplasticity.ItsoverexpressionisinvolvedinAD[86].Itisalsoinvolvedtocontrolthetightlycoordinatedprocessoffission/fusioninmitochondria(parra)andthusit inducesmitochondrialdefectsseeninagingandAD[87].MoreoverRCAN1increasessusceptibilitytooxidativestress.

12


S100β•

S100βexpressionlevelsareincreasedinbothDSandADastrocytesinassociationwithneuriticplaques[88].Inaddition,chronicoverexpressionofS100βcontributestoincreasedneuronalandneuriticAPPexpressionwithconsequentacceleratedamyloiddeposition,aswellasabnormalgrowthofneuritesinβ-amyloidplaques,similartoobservationsinmiddle-agedDSpatients[89].

SOD1•

TheSOD1 is localized in theneocortexandhippocampus from individualswithDSorAD[41].TheSOD1activity is increasedandnotcompensatedbycatalaseorGPXthusleadingtotheoverproductionofROS.

SOD1 overexpression induces aberrant neuronal and mitochondrial proteins inhippocampusof transgenicmice [90]andalters the20Sproteasomeduringaging[91,92].Theanti-oxidantsystemisaffectedinDSandthisdefectisworstenedduringaging[40].ItisalsoalteredinAD[42].

Synaptojanin•

Thephosphoinositidephosphatasesynaptojanin1(SYNJ1)iskeyregulatorofsynapticfunctionSynaptojanin(Synj)andadualphosphatasewhichregulatestheHedgehogpathway(Hh).IthasbeenshownthatreductionofSynaptojanin1(SYNJ1),themainphosphoinositol(4,5)-biphosphate phosphatase (PI(4,5) P2-degrading enzyme) in the brain and synapses,acceleratesAβclearanceinADmicemodel[93].ItisoverexpressedinDSbrainandinAPOE4carrierswithearlyADandhighlyoverexpressedinindividualswithDS/AD[94].

SynaptojaninisinvolvedinthehomosostasisofinositolscompoundsandisoverexpressedinDSbrain[95].ItsmetabolismisalteredinthebrainofTs65Dnmice,themostcommonlyusedmodelofDS.ThisdefectisrescuedbyrestoringSYNJ1todisomyinTs65DnmiceandisrecapitulatedintransgenicmiceoverexpressingSYNJ1fromBACconstructs[96].IthasbeenshowntobeinvolvedintheaginghippocampusmemorydeficitsinthremodelsofAD[97].

5. Animal Models to Study AD in DS Models

ThefirstmodelsforDownsyndromeweretransgenicmiceforsomekeygenessuchasSOD1,APP,S100βandCBSandsomeknout-miceforsomeofthemwerealsousefultounderstandtheroleofsomeofthesegeneseithersolelyor inacomplexgenotype.Humanchromosome21hasorthologousgenesonMMU16,17and10andmostofthepartialtrisomicmurinemodelshavebeenreviewedin[81;98].

Thefirstpartialtrisomicviablemodel,Ts65Dn,hasbeendevelopedbyMurielDavisson

13


intheearly90’s[99]andistrisomicforabout120orthologsofHsa21proteinencodinggenesthroughasegmentaltrisomyforMmu16butitcontainsalsoasegmentofabout10MboftheMmu17,whichcontains60proteinencodinggenes,noneofwhicharehomologoustoHsa21genes

Anothermousemodel forDS,Ts1Cje,hasshorterMmu16 trisomy than theTs65Dnmouse,contains62orthologsofHsa21genes,andexcludesthegenesegmentcontainingAPPandSOD1.

TheMs1Ts65micearetrisomicfortheregionofdifferencebetweenTs1CjeandTs65Dn,contains56orthologsofHsa21geneswithingeneticsegmentfromMrp139toSod1.AnotherrelativelynovelmodelforDSistheTs2CjemousemodelTs(Rb(12.1716))2Cje(Ts2).

AmoreaccuratemousemodelforDSmodelhavebeendevelopedbytheteamofYuthatcarriescompleteaneuploidy(spanningtheentireHsa21syntenicregion)thetripleaneuploidmicecontainstheMmu10(Ts1Yey),theMmu17(Ts2Yey)andtheMmu16(Ts3Yey).

AnotableDSmodelwascreatedfromthetrans-speciesinsertionofHsa21.TheTc1mousemodelforDScarriesmostofhumanchromosome21inadditiontothenormalcomplementofmousechromosomes,andistrisomicforapproximately212Hsa21protein-encodinggenesbutnottheAPPgene[100].

Therelationshipsbetwwenthesemodelsandtheirproperties inrelationtoalzheimerdiseasearepresentedin[101,102].

DSmousemodelshavealsobeeninvestigatedforbetterunderstandingtheroleofdifferentgenesegmentsofHsa21onADpathologyandmemoryimpairmentassociatedwithDSAD.In thesemodels someof theDScharacteristicshavebeen investigated regardingcognitivedeficitsbiologicalmechanismsinvolvedinDSADincludingextracellularamyloidβprotein(Aβ)accumulation,intraneuronalneurofibrillarytangles(NFTs)deposition,BFCNcellloss,neuronlossinlocuscoeruleus(LC),hippocampalabnormalities,imbalanceofneurotrophicfactors,alterationsinlong-termpotentiation(LTP),abnormalendosomalsignaling,presenceofneuroinflammationandoxidativestressandmorerecentlyneurotransmitters.

The results obtained in these different models have been reported in recent studies [101;103]andmostofthemhavebeenusedtopre-clinicalapproaches.Morerecentlyanewmodel for studyingADandespeciallypreclinical stageshavebeendeveloppedusinga ratinjectedbyadeno-associatedviruses(AAV)codingforhumanmutantAPP751containingtheSwedishandLondonmutationsandPS1(theM146Lmutation)cDNAsintothehippocampiadultrats[104].

Beforedescribingthepre-clinicalapproaches,wewilldeveloppedasmallparagraph

14


onneurotransmittersaswethinkthattheabnormalitiesinneurotransmitterscontentshavenotbeenenoughconsideredinpreclinicalapproaches.

5.1. Neurotransmitters

Themonaminesystemhasbeenstudiedinafewstudieseitherfrompost-mortembraintissuesfromindividualswithADorDSorbothDSADandinsomeanimalmodels.Brieflyin human tissues, a reduction of noradrenergic and serotonergic pathwaysweremeasuredpathways inDSADversusearlyonsetofAD(EOAD)and toa lesserextent inDSversuscontrols[20].DSandDSADpresentsimilarmonaminergicprofileswhichmightberelatedtoearlyamyloiddepositioninDS.

ArecentstudywasperformedonAPP/PS1mice[12]andshowednoageeffectincontrolmiceaccordingtoage6,12,16,24monthsbutaregionsepcificchangesforallmonoaminesin18monthsAPP/PS1micecomparedtocontrols.

ThemonoaminespathwaysevaluatedinyoungTs65Dnmiceversuscontrolsshowedthat a) the noradrenergic systemwasmainly affected by aging and not aneuploidy, b) thedopaminergicsystemwasbarelyaffectedinTs65Dn,c)theserotonergicwasreduced(5-HTand5-HIAAlevels)inthehippocampusofyoungTs65Dnversuscontrolsbutnotinagedones[105].Theseresultsarequitedifferentfromthoseobtainedtransgenicmiceoverexpressingthe singleDYRK1A showingmajor deficits in serotonin contents for the four brain areasandmajordeficitsindopamineandadrenalinecontentsespeciallyinthehypothalamus[82].Thesedifferencesbetweenthetwostudiesmightbeduetocompensationbetweendifferentchromosome21genesandnonchromosome21genespresentintheTs65Dnmice.

ThesametypeofstudiesshouldbeperformedontransgenicmiceforimportantT21genesrelatedtoDSandneurotransmissionasitwasdoneforCBStrangenicmice[76]andalsoinothermodelsofT21especiallyinratmodelswhichseemtobemoreaccuratetostudyADinDS[106].

Neurotransmitters-basesstrategiesareplausiblefortargetingcognitivedeclineinADandDS[107,108].

6. Pre-Clinical Approaches for AD in DS Models

A) Search for biomarkers

Inthesametimeasresearchersaretryingtofindtherapeuticalapproaches,muchworkisdonetofindbiomarkersfortheconversionofADinindividualswithDS.ThesebiomarkersfoundeitherinDSorinADnonDSwillbenefitforbothofthepopulations.

InDS, the higher levels ofAβ40 orAβ42/Aβ40 correlateswith the onset ofAD in

15


DS.TheformationoftanglesiscorrelatedwithcognitivedeclineandPETstudiesofglucosemetabolismmightprovideevidenceofbrainatrophyandADchanges inDS.Moreoverasreported in the review by [109], many other markers show either decreases or increases;proNGF,MMP’1,TNFα,IL6,IL-10,SAH,SAM/SAH(fromthechromosome21CBSgene)exhibithigherlevelswhileserumMHPG,CSForexinAshowlowerlevels.

The combined use of DYRK1, BDNF (brain-derived neurotrophic factor) andhomocysteinemeasuredinthebloodoftwounrelatedADpatientcohortsandage-matchedcontrolshasshowedtogiveasensitivityof0.952,aspecificityof0.889andanaccuracyof0.933intestingforAD[110].ThesameapproachiscurrentlyusedforDSintheprogressionofDSAD.

TheratmodelusingAAV(AAV-AD)identifiedintheplasmaofthevariousagedanimals41proteinsat8monthsand21proteinsat30monthswhicharespecificallydysregulatedinthecourseofADpathologyandthusidentifyingseveralstepsbeforeacuteclinicalhallmarks[104].

B) Inhibition of some DSAD hallmarks

Oxidative stress is a link betwwenAD and DS [111]. Although since many years,treatmentshavebeenfocusedonantioxidantswithoutrealtherapeuticalprogress,astudyshednewlightattheantioxidantstatusinthebloodofDSchildren,beforeandafter6monthsofdailyantioxidantsupplementationwithvitaminsEand C[112]. Beforetheantioxidanttherapy,DSpatientspresenteddecreasedGSTactivityandGSHdepletion;elevatedSOD,CAT,GR,GGTandMPOactivities;increaseduricacidlevels;whileGPxandG6PDactivitiesaswellasvitaminEandTBARSlevelswereunaltered.Aftertheantioxidantsupplementation,SOD,CAT,GPx,GR,GGTandMPOactivitiesweredownregulated,whileTBARScontentswerestronglydecreasedinDS.ThesametypeofstudyshouldbedoneastheresultobtainedinasurveyoftrialswithvitaminEonlyinmildcognitiveimpairmentandAlzheimer’sindividualsfailtoimprovecognitivefunction,globalseverityoractivitiesofdailyliving[113]. Otheranti-oxidantcompoundsshouldbemoreinvestigated:CoenzymeQ10,curcumintoinduceBDNF,melatonin.

Inflammatory processes in BFCN degeneration can be modulated by minocycline-treatment which inhibits microglial activation, prevents progressive BFCN decline andmarkedlyimprovesperformanceoftheTs65Dnmiceonaworkingandreferencememorytask[114].

mTOR signalling and its aberrant modulation in DS andAD age-related cognitive-declineaffectscrucialneuronalpathways.ItwasrecentlyreportedthatintranasalrapamycinereversemanyADhallmarks. Indeed in theTs65Dnmice this treatment could reduceAPP

16


levels,APPprocessingandAPPmetabolitesproduction,aswellas,tauhyperphosphorylationandareductionofoxidativestressmarkers[115].

Modulationofneurotransmission.ThegroupofSahelihasfocusedsincemanyyearson-thepossiblitythatneurotransmitter-basedstrategiesandmoresepcificallythenoradrenergicsystemcouldbeatargettherapyforDSandAD[107;108].TheGABAergicsystemisalsoagoodapproachandtheuseof antagonistsofGABAreceptorsincludingpentylenetetrazol(PTZ)toreduceperturbationsoftheexcitatory/inhibitorybalancetowardsanexcessofGABAmightbefructfuldespitenegativeresultsuptodate [81;116]. Neurodegenerationcanalsobeat leastpreventedbyestrogen treatmentwhichpartially rescuedworkingmemory (T-mazetest)andpreventedneurodegenerationinagedTs65Dnanimals(11to17-monthsold)[117,118].

Regarding the endosomeabnormalities,partially reductionofβ-secretase1 (BACE1)-bydeletingoneBACE1 alleleblockeddevelopmentofage-relatedendosomeenlargementinthemedial septalnucleus, cerebralcortexandhippocampus,andprevented lossofcholineacetyltransferase (ChAT)-positive medial septal nucleus neurons. It was also reported thepossibility thatstudies focusedondysregulationofsignalingendosomemay identifysometherapeutictargetsforpreventingDSAD[10].

Exosomehasbeenshownasatherapeuticapproachforneurodegenerativedisease- [120]. ExosomesecretionisenhancedinthebrainsofDSpatients,inamousemodelofthediseaseandinDSfibroblasts.Furthermore,increasedlevelsofthetetraspaninCD63,aregulatorofexosomebiogenesis,wereobservedinDSbrains.AsCD63knockdowndiminishedexosomereleaseandworsenedendosomalpathology inDSfibroblasts, itwasshown in theTs65Dnmicethat the increasedCD63expressionenhancedexosomerelease tomitigateendosomalabnormalitiesinDS[121].ExosomemightbeabiomarkerforADinDS[122].

APPmetabolismmodulation-

Itwasshownthatlong-termexposuretoenvironmentalenrichmentreducesAβoligomersandrescuesspatial-memoryabilitiesin12-month-oldtrisomicmice[123].

TheTs65Dnmice,asamodel forDSandalsoforDSADhasbeenusedfor immunisationagainstAbetaoligomers[124].IntheStatesAC ImmuneandUCSD represents the firstmajorclinicaltrialbyapharmaceuticalcompanyforAlzheimer’sintheDownsyndromepopulation.Thestudyisfocusedondevelopingavaccinethattargetstheaminoacidsof the Aβ peptides specifically involved in their misfolding, thus preventing theiraggregation,theformationandplaqueaccumulation,andpromotingplaqueremoval.

InhibitionofDYRK1A-

17


EGCG(Epigallocatechin-3-gallate)inhibitsDYRK1AactivityinvitroinseveralmurinemodelsofDSandmicetreatmentwithEGCGrestoressomeoftheDS-associateddeficitspresentinthesemodels[79].EGCGisnotonlyaninhibitorofthebiologicalactivityofDYRK1AbutitalsobindstheTauproteininitsphosphorylatedregion,hinderingtheaccessofthisregiontosomekinaseandmodyfyingthetridimentionalstructureoftheprotein.ThesethreecombinedfunctionsofEGCGregardingTauproteinpreventitsaggregationwhichisakeyprotagonistofneuronalcelldeath[125].EGCGshowsprotectiveeffectsagainstAβ-inducedneurotoxicityandregulatessecretoryprocessingofsAPPαviathePKCpathway.AdministrationofEGCG(2mg/kg)tomicefor7or14dayssignificantlydecreasedmembrane-boundholoproteinAPPlevels,withaconcomitantincreaseinsAPPαlevelsinthehippocampus.TheroleofEGCGinrelationtoADisreveiwedby[126].CombinedtreatmentwithenvironmentenrichmentandEGCGameliorateslearningdeficitsandhippocampalalterationsinTs65Dnmice[127].NewDYRK1Ainhibitorsarecurrentlystudiesinamnylaboratories[128,129].

C) Induced pluripotent stem cell (IPs) and deciphering AD in DS

Theuseorpluripotentstemcelltechnologyhasgivendramaticincreaseinourpossibilityforabetterknowledgeofthemecanismandthedevelopmentofdrugsinneurodegenerativedisease [130].A new inhibitor ofDYRK1A, nammedALGERNON (altered generation ofneurons)wasfoundinascreenforofneuralstemcells(NSCs)[131].ThiscompoundwasfoundtorescueproliferativedeficitsinTs65Dn-derivedneurospheresandhumanNSCsderivedfromindividualswithDS.Moreover,administrationofALGERNONtopregnantTs1CJedamsrescuedaberrantcorticalformationinDSmouseembryosandpreventedthedevelopmentofabnormalbehaviorsinDSoffspring.ThesedatasuggestthattheneurogenicphenotypeofDScanbepreventedbyALGERNONprenataltherapy.AspartoftheneurogenicphenotypeisalsoconnectedtoAD,thistypeofexperimentscanleadtofurtherevaluateifthesecorrectedmicewillpresentalsosomerescueoftheDSADphenotypealthoughtheTs1CjemicedonothavetheAPPgeneintriplicate.

AnotherrecentstudyshowpromissingresultsregardingAD,bytheuseofpluripotentIPScfromDSindividuals[132].ItcouldbeshownthatinvitrogeneratedDSneuralcellshaveabnormalAβmetabolismandincreasedexpressionofAD-associatedchromosome21genes(BACE2,RCAN1,ETS2).TheseresultsshowthatitispossibletostudyAD-typepathologythroughthestudyofIPSCfromDSindividuals.

7. Conclusions

The close relationshipsbetween chromosome21genes involved in theonset ofADinthegeneralpopulationandtheirpresenceinthirdcopiesinindividualswithDSyieldnewopportunitiestobetterunderstandthecourseofAD,findbiomarkersandinnovativetherapiesforAD in thegeneral population (SAD) through theprecise studyof the courseofAD in

18


this special geneticpopulation (DSAD). It is crucial to identifybiomarkers forAD in thispopulationsoastobeabletodeterminetheefficacyofanynewtreatmentearlyinthecourseoftheunderlyingdiseaseprocessandwellbeforetheAD-relatedpathologyandcerebralatrophyhavebecomeestablished.ThusthenumerousmicemodelspresentforDSandtheircombinationwithotherssuchasthosesilencingspecificchromosome21geneareandwillbeveryusefultoassaynewdrugtherapies.ButmicearenotmenandthemainimportantpersonsarethosewithDSorADorboth.Inthatperspective,theEuniceKennedyShriverNationalInstituteofChildHealthandHumanDevelopment(NICHD)andtheNationalInstituteonAging(NIA),bothpartsoftheNationalInstitutesofHealth,arepartneringonaninitiativetoidentifybiomarkersandtracktheprogressionofAlzheimer’sDiseaseinadultswithDS.MoreoverACImmuneandUCSDaretryingtodevelopforindividualswithDSavaccinespecificfortheabnormalfoldingoftheabetapeptides.

8. References

1.BekrisLM,YuCE,BirdTD,TsuangDW.GeneticsofAlzheimerdisease.JGeriatrPsychiatryNeurol.2010;Dec;23(4):213-27.

2.SelkoeDJAlzheimer’sDiseaseColdSpringHarbPerspectBiol.2011;Jul;3(7):a004457.

3.RikkiHullingeraandLuigiPuglielliaMolecularandcellularaspectsofage-relatedcognitivedeclineandAlzheimer’sdiseaseBehavBrainRes.2017;March30;322(PtB):191–205;doi:10.1016/j.bbr.2016.05.008.

4.ThalDR,RubU,OrantesM,BraakHPhases ofAbeta-deposition in the humanbrain and its relevance for thedevelopmentofAD.Neurology2002:58:1791-800.

5.GötzJEckertA,MatamalesM,IttnerLM,LiuXModesofAbetatoxicityinAlzheimerdisease.CellMolLifeSci.2011;68:3359-3375.

6.KopkeE,TungYC,ShaikhS,AlonsoAC,IqbalK,Grundke-IqbalIMicrotubule-associatedproteintau:Abnormalphosphorylation of a non- paired helical filament pool inAlzheimer disease. J Biol Chem 1993; 268(32): 24374-24384.

7.BraakH,BraakEStagingofAlzheimer’diseaserelatedtoneurofibrillarychanges.NeurobiolAging1995;16:271-278(discussion278-284).

8.JinM,ShepardsonN,YangT,ChenG,WalshD,SelkoeDJSolubleamyloidβ-proteindimersisolatedfromAlzheimercortex directly induceTauhyperphosphorylation and neuritic degenerationProcNatlAcad SciUSA. 2011;Apr 5;108(14):5819–5824.Publishedonline2011;Mar18.

9.ŠimićG,BabićLekoM,WrayS,HarringtonCR,DelalleI,Jovanov-MiloševićN,BažadonaD,BuéeL,deSilvaR,DiGiovanniG,WischikCM,HofPRMonoaminergicneuropathologyinAlzheimerdiseaseProgNeurobiol2017;151:101-138.

10.ChenXQSawaM,MobleyWCFreeRadicBiolMedDysregulationofneurotrophinsignalinginthepathogenesisofAlzheimerdiseaseandofAlzheimerdiseaseinDownsyndrome2018;114:52-61.

11.TrilloL,DasD,HsiehW,MedinaB,MoghadamS,LinB,DangV,SanchezMM,DeMiguelZ,AshfordJW,SalehiA.Ascendingmonoaminergic sytemsalterations inAlzheimer’sdisease.Translatingbasic science intoclinical careNeuroscBiobehavReviews2013;37:1363-1379.

12.VonLinstowCU,SeverinoM,MetaxasA,WaiderJ,BabcockAA,LeschKP,GramsbergenJB,FinsenBEffectof

19


agingandAlzheimer’sdisease-likepathologyonbrainmonoaminesinmice.NeurochemIntern.2017;108:218-245.

13.LottITNeurologicalphenotypesforDownsyndromeacrossthelifespanProgBrainRes.2012;197:101-21.

14.WisniewskiKEetalPrecociousaginginpatientswithDown’ssyndrome.BiolPsychiatry.1978;13(5):619-27.

15.WisniewskiKEWisniewskiHM,WenGYOccurrenceofneuropathologicalchangesanddementiaofAlzheimer’sdiseaseinDown’ssyndromeAnnNeurol1985;3:278-82.

16.MannDMA,EsiriMMThepatternofacquisitionofplaquesandtanglesinthebrainofpatientsunder50yearsofagewithDown’ssyndrome.JNeurSci1989;89:169-179.

17.PrasherVP,FarrerMJ,KesslingAM,FisherEM,WestRJ,BarberPC,ButlerAC.etal.MolecularmappingorAlzheimer-typedementiainDown’ssyndromeAnnNeurol1998;43:380-383.

18.DoranE,KeatorD,HeadE,PhelanMJ,KimR,TotoiuM,BarrioJR,GaryW.SmallGW,PotkinSG,LottITDownsyndrome,partialtrisomy21,andabsenceofAlzheimer’sDisease:theroleofAPPJAlzheimerDis2017;56(2):459-470.

19.HeadE.LottIT,WilcockDM,LemereCAAginginDownsyndromeandtheDevelopmentofAlzheimer’sdiseaseNeuropathologyCurrAlzheimerRes2016;13(1):18–29.

20.DekkerAD,VermeirenY,Carmona-IraguiM,BenejamB,VidelaL,GelpiE,AertsT,DVanDamD,FernándezS, LMartin JJ Monoaminergic impairment in Down syndrome withAlzheimer’s disease compared to early-onsetAlzheimer’sdisease.AlzheimersDement(Amst)2017;10:99-111.

21.BallSL,HollandAJ,HuppertFA,TreppnerP,WatsonP,HonJ.etalThemodifiedCAMDEXinformantinterviewisavalidandreliabletoolforuseinthediagnosisofdementiainadultswithDown’ssyndromeJIntellectDisabil2004;Res48:611-620.

22.WalshDM,DoranE,SilvermanW,TournayA,MovsesyanN,LottITRapidAssessmentofCognitiveFunctioninDownsyndromeAcrossIntellectualLevelandDementiaStatusJIntellectDisabilRes2015;59(11):1071-1079.

23.DekkerAD,VermeirenY,BeugelsdijkG,SchippersM,HassefrasL,EleveldJ,GrefelmanS,FopmaR,Bomer-VeenboerM,OosterlingGDE,ScholtenE,TollenaereM,VanGoethemG,ZuEulenburgC,CoppusAMW,DeDeynPP.TheBehavioralandPsychologicalSymptomsofDementiainDownSyndrome(BPSD-DS)Scale:ComprehensiveAssessmentofPsychopathologyinDownSyndromeJAlzheimer’sDis.2018;63:797-820.

24.ZisP,StrydomAClinicalaspectsandbiomarkersofAlzheimer’sdiseaseinDownsyndromeFreeRadicalBiologyandMedicine2018;114,3-9.

25.MathisCA,WangY,KlunkWE.Imagingbeta-amyloidplaquesandneurofibrillarytanglesintheaginghumanbrain.CurrPharmDes.2004;10(13):1469-92.Review

26.NelsonLD,SiddarthP,KepeV,ScheibelKE,HuangSC,BarrioJR,SmallGW.Positronemissiontomographyofbrainbeta-amyloidandtaulevelsinadultswithDownsyndromeArchNeurol.2011Jun;68(6):768-74.

27.AnnusTWilsonLR,HongYTetalThepatternofamyloidaccumulationinthebrainsofadultswithDownsyndrome.AlzheimersDement.2016;May12(5):538-45.

28.DiDomenicoF,TramutolaA,FoppoliC,HeadE,PerluigiM,ButterfieldDAmTORinDownsyndrome:RoleinAßandtauneuropathologyandtransitiontoAlzheimerdisease-likedementia.FreeRadicBiolMed.2018Jan;114:94-101.

29.LaoPJ,HandenBL,BetthauserTJ,MihailaI,HartleySL,CohenAD,TudorascuDL,BulovaPD,LoprestiBJ,TumuluruRV,MuraliD,MathisCA,BarnhartTE,StoneCK,PriceJC,DevennyDA,MailickMR,KlunkWE,JohnsonSC,ChristianBT.Longitudinalchangesinamyloidpositronemissiontomographyandvolumetricmagneticresonance

20


imaginginthenondementedDownsyndromepopulation.AlzheimersDement(Amst).2017May23;9:1-9.

30.HartleySL,HandenBL,DevennyD,MihailaI,HardisonR,LaoPJ,KlunkWE,BulovaP,JohnsonSC,ChristianBTCognitivedeclineandbrainamyloid-βaccumulationacross3yearsinadultswithDownsyndromeNeurobiolAging2017;Oct58:68-76.

31.NealeN,PadillabC,FonsecabLM,HollandbT,ZamanbSNeuroimagingandothermodalitiestoassessAlzheimer’sdiseaseinDownsyndromeNeuroImageClin2018;17,263–271.

32.AugustinackJC,SchneiderA,MandelkowE-M,HymanBTSpecifictauphosphorylationsitescorrelatewithseverityofneuronalcytopathologyinAlzheimer’sdisease.ActaNeuropathol.2002;103:26-35.

33.RubinszteinDCHonJ,StevensF,PyrahI,TysoeC,HuppertFA,EastonDF,HollandAJApoEgenotypesandriskofdementiainDownsyndrome.AmJMedGenet.1999;88(4):344-347.

34.CastellanoJM,KimJ,StewartFR,JiangH,DeMattosRB,PattersonBW,FaganAM,MorrisJC,MawuenyegaKG,CruchagaC,GoateAM,BalesKR,PaulSM,BatemanRJ,HoltzmanDM.HumanapoEisoformsdifferentiallyregulatebrainamyloid-βpeptideclearance.SciTranslMed2011;Jun293(89):89ra57.

35. Day RJ,McCarty KL, Ockerse KE, Head E, RohnTTProteolytic Cleavage ofApolipoprotein E in the DownSyndromeBrainAgingDis.2016;7(3):267-277.

36.Wilcock DM, Schmitt FA, Head E Cerebrovascular contributions to aging andAlzheimer’s disease in Downsyndrome.BiochimBiophysActa2016;1862(5):909-14.

37.HelmanAM,SieverM,McCartyKL,LottIT,DoranE,AbnerEL,SchmittFA,HeadEMicrobleedsandCerebralAmyloidAngiopathyinthebrainsofpeoplewithDownsyndromewithAlzheimer’sdisease.JAlzheimersDis2018;Nov15.

38.HeadE,PowellDK,SchmittFA.MetabolicandvascularimagingbiomarkersinDownsyndromeprovideuniqueinsightsintobrainagingandAlzheimerdiseasepathogenesis.FrontAgingNeurosci2018;Jun21;10:191.

39.JovanovicSV,ClementsD,MacLeodKBiomarkersofoxidativestressaresignificantlyelevatedinDownsyndrome.FreeRadicalBiology&Medicine1998;9:1044-1048.

40.PerluigiM,ButterfieldDAOxidativestressandDownsyndrome:aroutetowardAlzheimer-likedementia.CurrGerontolGeriatrRes.2012;724904.

41.FurutaAPriceDL,PardoCA,TroncosoJC,XuZS,TaniguchiN,MartinLJ.LocalizationofthesuperoxidedismutasesinAlzheimer’sdiseaseandDown’ssyndromeneocortexandhippocampus.AmJPathol.1995116(2):367-72.

42.TramutolaA,LanzillottaC,PerluigiM,ButterfieldDAOxidativestress,proteinmodificationandAlzheimerdisease.BrainRes.Bull.2017;133:88-96.

43. ButterfieldDA, Boyd-Kimball DRedox proteomics and amyloid β-peptide: insights intoAlzheimer disease. JNeurochem2018.

44.BusciglioJPelsmanA,WongC,PiginoG,YuanM,MoriH,YanknerBAAlteredmetabolismoftheamyloidbetaprecursorproteinisassociatedwithmitochondrialdysfunctioninDown’ssyndrome.Neuron2002;33:677-688.

45.CoskunPE,WyrembakJ,DerberevaO,MelkonianG,DoranE,LottIT,HeadE,CotmanCW,WallaceDCSystemicmitochondrialdysfunctionandtheetiologyofAlzheimer’sdiseaseandDownsyndromedementia.JAlzheimersDis2010;20Suppl2:S293-310.

46.MoreiraPI,CarvalhoC,ZhuX,SmithMA,PerryGMitochondrialdysfunctionisatriggerofAlzheimer’sdiseasepathophysiology.BiochimBiophysActaBBA-Mol.BasisDis2010;18022-10.

47.ValentiD,BraidyN,DeRasmoD,SignorileA,RossiL,AtanasovAG,VolpicellaM,Henrion-CaudeA,Nabavi

21


SM,VaccaRAMitochondriaaspharmacologicaltargetsinDownsyndrome.FreeRadicalBiologyandMedicine2018;114:69-83.

48.CataldoAM,PetanceskaS,TerioNB,PeterhoffCM,DurhamR,MerckenM,MehtaPD,

a.BuxbaumJ,HaroutunianV,NixonRAAbetalocalizationinabnormalendosomes:associationwithearliestAbetaelevationsinADandDownsyndromeNeurobiolAging2004;25(10):1263-72.

49.CorlierF,RivalsI,LagardeJ,HamelinL,CorneH,DauphinotL,AndoK,CossecJC,FontaineG,DorotheeG,Malaplate-ArmandC,OlivierJL,DuboisB,BottlaenderM,DuyckaertsC,SarazinM,PotierMCClinicalImaBio3TeamModificationsoftheendosomalcompartmentinperipheralbloodmononuclearcellsandfibroblastsfromAlzheimer’sdiseasepatientsTranslPsychiatry2015;5(7):e595.

50.CossecJC,LavaurJ,BermanDE,RivalsI,HoischenA,StoraS,RipollC,MircherC,GrattauY,OlivomarinJC,deChaumontF,LecourtoisM,AntonarakisSE,VeltmanJA,DelabarJM,DuyckaertsC,DiPaoloG,PotierMCTrisomyforsynaptojanin1inDownsyndromeisfunctionallylinkedtotheenlargementofearlyendosomes.HumMolGenet.2012;21(14):3156-72.

51.PotterH,GranicAandCaneusJRoleofTrisomy21MosaicisminSporadicandFamilialAlzheimer’sDiseaseCurrAlzheimerRes.2016;13(1):7-17.Review.

52.SinaiAMokryszC,BernalJ,PredictorsofAgeofDiagnosisandSurvivalofAlzheimer’sDiseaseinDownSyndromeJournalofAlzheimer’sDisease2018;61717-728.

53.LeverenzJ,RaskindMAEarlyamyloiddepositioninthemedialtemporallobeofyoungDownsyndromepatients:Aregionalquantitativeanalysis.ExpNeurol1998;150:296-304

54.GyureKADurhamR,StewartWF,SmialekJE,TroncosoJCIntraneuronalAbeta-AmyloidprecedesdevelopmentofamyloidplaquesinDownsyndrome.ArchPatholLabMed.2001;125:489-492.

55.GlabeCIntracellularmechanismsofamyloidaccumulationandpathogenesisinAlzheimer’sDisease.JMolNeurosci2001;17:137-145.Review.

56.HirayamaA,HorikoshiY,MaedaM,ItoM,TakashimaSCharacteristicdevelopmentalexpressionofamyloidbeta40,42and43inpatientswithDownsyndrome.Brain&Development2003;25:180-185.

57.SchupfN,ZigmanWB,TangMX,PangD,MayeuxR,MehtaP,SilvermanWChangeinplasmaAßpeptidesandonsetofdementiainadultswithDownsyndromeNeurology2010;Nov2;75(18):1639-44.

58.PrasherVPSajithSG,MehtaP,ZigmanWB,SchupfNPlasma-betaamyloidanddurationofAlzheimer’sdiseaseinadultswithDownsyndrome.IntJGeriatrPsychiatry2010;25(2):202–207.

59. JenningsDSeibyl J,SabbaghM,LaiF,HopkinsW,BullichS,GimenezM,ReiningerC,PutzB,StephensA,CatafauAM,MarekK.Agedependenceofbrainβ-amyloiddepositioninDownsyndrome:An[18F]florbetabenPETstudyNeurology2015;Feb3;84(5):500-7.

60.HartleySL,HandenBL,DevennyD,MihailaI,HardisonR,LaoPJ,KlunkWE,BulovaP,JohnsonSC,ChristianBTCognitivedeclineandbrainamyloid-βaccumulationacross3yearsinadultswithDownsyndrome.NeurobiolAging2017;Oct;58:68-76.

61.DavidsonYS,RobinsonA,PrasherVP,MannDMA.TheageofonsetandevolutionofBraaktanglestageandThalamyloidpathologyofAlzheimer’sdiseaseinindividualswithDownsyndrome.ActaNeuropatholCommun2018;Jul4;6(1):56.

62.DiDomenicoFPupoG,MancusoC,BaroneE,PaoliniF,ArenaA,BlarzinoC,SchmittFA,HeadE,ButterfieldDA,PerluigiMBach1overexpressioninDownsyndromecorrelateswiththealterationoftheHO-1/BVR-asystem:insightsfortransitiontoAlzheimer’sdisease.JAlzheimersDis2015;44(4):1107-1120.

22


63. Barone E, Head E, Butterfield DA, Perluigi M HNE-modified proteins in Down Syndrome: involvement indevelopmentofAlzheimerdiseaseneuropathology.FreeRadicBiolMed.2017;111:262-269.

64.PetersDGConnorJR,MeadowcroftMDTherelationshipbetweenirondyshomeostasisandamyloidogenesisinAlzheimer’sdisease:twosidesofthesamecoin.NeurobiolDis2015;Sep;81:49-65.

65.BaroneE,ArenaA,HeadE,ButterfieldDA,PerluigiMDisturbanceofredoxhomeostasisinDownSyndrome:Roleofirondysmetabolism.FreeRadicalBiologyandMedicine2018;11484-93.

66.Antonarakis SELyleR,Dermitzakis ET,ReymondA,Deutsch SChromosome 21 andDown syndrome: fromgenomicstopathophysiology.NatRev.Genet2004;Oct;5(10):5725-738.Review.

67.LeeJHLeeAJ,DangLH,PangD,KisselevS,Krinsky-McHaleSJ,ZigmanWB,LuchsingerJA,SilvermanW,TyckoB,ClarkLN,SchupfNCandidategeneanalysisforAlzheimer’sdiseaseinadultswithDownsyndromeNeurobiolAging2017;56:150-158.

68.GalzitskayaOVSurinAK,GlyakinaAV,RogachevskyVV,SelivanovaOMShouldtheTreatmentofAmyloidosisBePersonified?MolecularMechanismofAmyloidFormationbyAβPeptideandItsFragmentsJAlzheimersDisRep2018;Oct24;2(1):181-199.

69.MatthiasGralleM,GralleBotelhoM,WoutersFSNeuroprotectiveSecretedAmyloidPrecursorProteinActsbyDisruptingAmyloidPrecursorProteinDimersJBiolChem.2009;May29;284(22):15016–15025.

70.HabibA,HouH,MoriT,TianJ,ZengJ,FanS,GiuntaB,SanbergPR,SawmillerD,TanJ.HumanUmbilicalCordBloodSerum-derivedα-Secretase:FunctionalTesting inAlzheimer’sDiseaseMouseModels.CellTransplant2018;27(3):438-455.

71.Hussain I,PowellDJ,HowlettDR,ChapmanGA,GilmourL,MurdockPR,TewDG,MeekTD,ChapmanC,SchneiderK,RatcliffeSJ,TattersallD,TestaTT,SouthanC,RyanDM,SimmonsDL,WalshFS,DingwallC,ChristieGASP1(BACE2)cleavestheamyloidprecursorproteinatthebeta-secretasesite.MolCellNeurosci2000;16(5):609-19.

72.NistorM,DonM,ParekhM,SarsozaF,GoodusM,LopezGE,KawasC,LeverenzJ,DoranE,LottIT,HillM,HeadEAlpha-andbeta-secretaseactivityasafunctionofageandbeta-amyloidinDownsyndromeandnormalbrain.NeurobiolAging2007;28(10):1493-506.

73.IchinoheA,KanaumiT,TakashimaS,EnokidoY,NagaiY,KimuraHCystathioninebeta-synthaseisenrichedinthebrainsofDown’spatients.BiochemBiophysResCommun2005;338(3):1547-50.

74.EtoKAsadaT,ArimaK,MakifuchiT,KimuraHBrainhydrogen sulfide is severelydecreased inAlzheimer’sdiseaseBiochemBiophysResCommun2002;May24293(5):1485-8.

75.LiuYDengY,LiuH,YinC,LiX,GongQHydrogensulfideameliorateslearningmemoryimpairmentinAPP/PS1transgenicmice:AnovelmechanismmediatedbytheactivationofNrf2.PharmacolBiochemBehav2016;150-151:207-216.

76.LondonJNdiayeFK,BuiLC,SouchetB,DaubigneyF,MagnanC,LuquetS,DairouJ,JanelN,RouchCAlterationsin the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain MolNeurobiol2018;sep20.

77.KimuraR,KaminoK,YamamotoM,NuripaA,KidaT,KazuiH,HashimotoR,TanakaT,KudoT,YamagataH,TabaraY,MikiT,AkatsuH,KosakaK,FunakoshiE,NishitomiK,SakaguchiG,KatoA,HattoriH,UemaT,TakedaMTheDYRK1Agene, encoded in chromosome21Down syndromecritical region, bridgesbetweenbeta-amyloidproductionandtauphosphorylationinAlzheimerdisease.HumMolGenet.2007;16(1):15-23.

78.WegielJ,KaczmarskiW,BaruaM,KuchnaI,NowickiK,WangKC,WegielJ,YangSM,FrackowiakJ,Mazur-KoleckaB,SilvermanWP,ReisbergB,MonteiroI,deLeonM,WisniewskiT,DaltonA,LaiF,HwangYW,Adayev

23


T,LiuF,IqbalK,IqbalIG,GongCXetal.LinkbetweenDYRK1Aoverexpressionandseveral-foldenhancementofneurofibrillarydegenerationwith3-repeattauproteininDownsyndrome.JNeuropatholExpNeurol.2011:70(1):36–50.

79.SouchetB,GuedjF,Penke-VerdierZ,DaubigneyF,DuchonA,HeraultY,BizotJC,JanelN,CreauN,DelatourB,DelabarJMPharmacologicalcorrectionofexcitation/inhibition imbalance inDownsyndromemousemodels.FrontBehavNeurosci2015;Oct20,9:267.

80.DelaTorreR,DeSolaS,HernandezG,FarréM,PujolJ,RodriguezJ,EspadalerJM,LangohrK,Cuenca-RoyoA,PrincipeA,XicotaL,JanelN,Catuara-SolarzS,Sanchez-BenavidesG,BléhautH,Dueñas-EspínI,DelHoyoL,BenejamB,Blanco-HinojoL,VidelaS,FitóM,DelabarJM,DierssenM;TESDADstudygroupSafetyandefficacyofcognitivetrainingplusepigallocatechin-3-gallateinyoungadultswithDown’ssyndrome(TESDAD):adouble-blind,randomised,placebo-controlled,phase2trial.LancetNeurol.2016;15(8):801-810.

81.HeraultYDelabarJM,FisherEMC,TybulewiczVLJ,YuE,BraultV.RodentmodelsinDownsyndromeresearch:impactandfutureopportunitiesDisModelMech2017;Oct1;10(10):1165-1186.

82.LondonJ,RouchC,BuiLC,AssayagE,SouchetB,DaubigneyF,MedjaouiH,LuquetS,MagnanC,DelabarJM,DairouJ,JanelNOverexpressionoftheDYRK1AGene(Dual-SpecificityTyrosinePhosphorylation-RegulatedKinase1A)InducesAlterationsoftheSerotoninergicandDopaminergicProcessinginMurineBrainTissues.MolNeurobiol2018;55(5):3822-3831.

83.WolvetangEW,BradfieldOM,TymmsM,ZavarsekS,HatzistavrouT,Kola I,HertzogPJThechromosome21transcriptionfactorETS2 transactivates thebeta-APPpromoter: implications forDownsyndromeBiochimBiophysActa2003;1628,105–110.

84.HelgueraPPelsmanA,PiginoG,WolvetangE,HeadE,BusciglioJets-2promotestheactivationofamitochondrialdeathpathwayinDown’ssyndromeneurons.JNeurosci.2005;25(9):2295-303.

85.LLoretABadiaMC,GiraldoE,ErmakG,AlonsoMD,PallardóFV,DaviesKJ,ViñaJAlzheimer’samyloid-βtoxicityandtauhyperphosphorylationarelinkedviaRCAN1JAlzheimersDis2011;27(4):701–709.

86.ErmakGandKelvinJ.A.DaviesKJAChronichighlevelsoftheRCAN1-1proteinmaypromoteneurodegenerationandAlzheimerdisease2013;FreeRadicBiolMed62:47–51.

87.WongH,LevengaJ,CainP,RothermelB,KlannE,HoefferCRCAN1overexpressionpromotesage-dependentmitochondrialdysregulationrelatedtoneurodegenerationinAlzheimer’sdiseaseActaNeuropathol2015;130(6):829-843.

88.GriffinWS,ShengJG,McKenzieJE,RoystonMC,GentlemanSM,BrumbackRA,CorkLC,DelBigioMR,RobertsGW,MrakRELife-longoverexpressionofS100betainDown’ssyndrome:implicationsforAlzheimerpathogenesisNeurobiolAging1998;19:401-405.

89.RoystonMC,McKenzieJE,GentlemanSM,ShengJG,MannDM,GriffinWS,MrakREOverexpressionofs100betainDown’ssyndrome:correlationwithpatientageandwithbeta-amyloiddeposition.NeuropatholApplNeurobiol1999;25:387-393.

90. Shin JH, London J, Le PecheurM,WeitzdoerferR,HoegerH, LubecGAberrant neuronal andmitochondrialproteinsinhippocampusoftransgenicmiceoverexpressinghumanCu/Znsuperoxidedismutase1FreeRadicBiolMed2004;37(5):643-53.

91.LePecheurM,BourdonE,PalyE,FaroutL,FriguetB,LondonJ.etalOxidizedSOD1altersproteasomeactivitiesinvitroandinSOD1overexpressingmiceFEBSletters2005;579:3613-8.

92.LondonJ,LePecheurM(2016)EffectofSOD1overexpressiononthe20SproteasomeduringagingNaturalScience2016;8:295-304.

24


93.ZhuLZhongM,ZhaoJ,RheeH,CaesarI,KnightEM,Volpicelli-DaleyL,BustosV,NetzerW,LiuL,LucastL, EhrlichME,RobakisNK,GandySE,CaiDReduction of Synaptojanin 1AcceleratesClearance andAttenuatesCognitiveDeteriorationinanAlzheimerMouseModelJBiolChem2013;288(44):32050-63.

94.MartinSB,DowlingAL,LianekhammyJ,LottIT,DoranE,MurphyMP,BeckettTL,SchmittFA,HeadEetalSynaptophysinandSynaptojanin-1inDownSyndromeareDifferentiallyAffectedbyAlzheimer’sDisease.JAlzheimersDis2014;42(3):767-775.

95.AraiYIjuinT,TakenawaT,BeckerLE,TakashimaSExcessiveexpressionofsynaptojanininbrainswithDownsyndrome.BrainDev.2002;24(2):67-72.

96.VoronovSV,FrereSG,GiovediS,PollinaEA,BorelC,ZhangH,SchmidtC,AkesonEC,WenkMR,CimasoniL,ArancioO,DavissonMT,AntonarakisSE,GardinerK,DeCamilliP,DiPaoloGSynaptojanin1-linkedphosphoinositidedyshomeostasis and cognitive deficits in mouse models of Down’s syndrome. Proc Natl Acad Sci USA 2008;105(27):9415-20.

97.MirandaAM,HermanM,ChengR,NahmaniE,BarrettG,MicevskaE,FontaineG,PotierMC,HeadE,SchmittFA,LottIT,Jiménez-VelázquezIZ,AntonarakisSE,DiPaoloG,LeeJH,HussainiSA,MarquerC.ExcessSynaptojanin1ContributestoPlaceCellDysfunctionandMemoryDeficitsintheAgingHippocampusinThreeTypesofAlzheimer’sDiseaseCellRep2018;23(10):2967-2975.

98.GuptaM,DhanasekaranAR,GardinerKJMousemodels ofDown syndrome: gene content and consequencesMammGenome2016;27(11-12):538–555.

99.DavissonMT,SchmidtC,AkesonECSegmental trisomyofmurine chromosome16: a newmodel system forstudyingDownsyndromeProgClinBiolRes1990;360,263-280.

100.O’DohertyA,RufS,MulliganC,HildrethV,ErringtonML,CookeS,SesayA,ModinoS,VanesL,HernandezD,LinehanJM,SharpePT,BrandnerS,BlissTV,HendersonDJ,NizeticD,TybulewiczVL,FisherEM.Ananeuploidmousestraincarryinghumanchromosome21withDownsyndromephenotypesScience2005;Sep23;309(5743):2033-7.

101.ChoongXYToshJL,PulfordLJ,FisherEMDissectingAlzheimerdiseaseinDownsyndromeusingmousemodels.FrontBehavNeurosci2015;Oct13;9:268.

102.HamlettED,BogerHA,LedreuxA,KelleyCM,MufsonEJ,FalangolaMF,GuilfoyleDN,NixonRA,PattersonD,DuvalN,GranholmACCognitiveImpairment,Neuroimaging,andAlzheimerNeuropathologyinMouseModelsofDownSyndromeCurrAlzheimerRes.2016;13(1):35-52.Review.

103.AzizNMGuedjF,PenningsJLA,Olmos-SerranoJL,SiegelA,HaydarTF,BianchiDWLifespananalysisofbraindevelopment,geneexpressionandbehavioralphenotypesintheTs1Cje,Ts65DnandDp(16)1/YeymousemodelsofDownsyndromeDisModelMech2018;Jun12;11(6)pii:dmm031013.

104.AudrainM,SouchetB,AlvesSβAPPProcessingDrivesGradualTauPathologyinanAge-DependentAmyloidRatModelofAlzheimer’sDiseaseCerebralCortex2017;1–18.

105.DekkerADVermeirenY,AlbacC,Lana-ElolaE,Watson-ScalesS,GibbinsD,AertsT,VanDamD,FisherEMC,TybulewiczVLJ,PotierMC,DeDeynPPetalAgingratherthananeuploidyaffectsmonoamineneurotransmittersinbrainregionsofDownsyndromemousemodelsNeurobiolDis2017;105:235-244.

106.XuH,WangZ,ZhuL,SuiZ,BiW,LiuR,BiK,LiQTargetedNeurotransmittersProfilingIdentifiesMetabolicSignatures in Rat Brain by LC-MS/MS:Application in Insomnia, Depression andAlzheimer’s DiseaseMolecules2018;23(9):2375.

107.DasD,PhillipsC,HsiehW,SumanthK,DangV,SalehiANeurotransmitter-basedstrategiesforthetreatmentofcognitivedysfunctioninDownsyndromeProgneurpharmacoBioPsychiatry2014;54:140-148.

108.PhillipsC,FahimiA,DasD,MojabiFS,PonnusamyR,SalehiANoradrenergicsysteminDownsyndromeand

25


Alzheimer’sdiseaseAtargetfortherapyCurrAlzheimerres.2016;13(1)68-83.Review.

109.LeeNCChienYH,HwuWLAReviewofBiomarkersforAlzheimer’sDiseaseinDownSyndrome.NeurolTher6(Suppl1)2017;69-81.

110.JanelN,AlexopoulosP,BadelA,LamariF,CamprouxAC,LagardeJ,SimonS,Feraudet-TarisseC,LamouretteP,ArbonesM,PaulJL,DuboisB,PotierMC,SarazinM,DelabarJMCombinedassessmentofDYRK1A,BDNFandhomocysteinelevelsasdiagnosticmarkerforAlzheimer’sdiseaseTranslPsychiatry2017;7(6):e1154.

111.ZanaM,JankaZ,KálmánJOxidativestress:abridgebetweenDown’ssyndromeandAlzheimer’sdiseaseNeurobiolAging2007;May28:648-76.Review.

112.ParisottoEB,GarletTR,CavalliVL,ZamonerA,daRosaJS,BastosJ,MickeGA,FrödeTS,PedrosaRC,WilhelmFilhoDAntioxidantinterventionattenuatesoxidativestressinchildrenandteenagerswithDownsyndromeResDevlDisabil2014Jun;35(2014)1228-1236.

113.FarinaN,LlewellynD,MGEKNI,TabetN.CochranedatabaseSystRev.2017:18;4:CD002854.

114. Hunter CL, Bachman D, GranholmACMinocycline prevents cholinergic loss in a mousemodel of Down’ssyndrome.AnnNeurol.2004Nov;56(5):675-88.

115.TramutolaA,LanzillottaC,BaroneE,ArenaA,ZulianiI,MoscaL,BlarzinoC,ButterfieldDA,PerluigiM,DiDomenicoFIntranasalrapamycinamelioratesAlzheimerlikecognitivedeclineinamousemodelofDownsyndrome.TranslationalNeurodegeneration2018;7:28.

116.ZorrilladeSanMartinJDelabarJM,BacciA,PotierMCGABAergicover-inhibition,apromisinghypothesisforcognitivedeficitsinDownsyndromeFreeRadicalBiologyandMedicine2018;114:33–39.

117.GranholmACSandersL,SeoH,LinL,FordK,IsacsonOEstrogenaltersamyloidprecursorproteinaswellasdendriticandcholinergicmarkersinamousemodelofDownsyndrome.Hippocampus2003;13(8):905-14.

118.HunterCLBimonte-NelsonHA,NelsonM,EckmanCB,GranholmACBehavioralandneurobiologicalmarkersofAlzheimer’sdiseaseinTs65Dnmice:effectsofestrogen.NeurobiolAging2004;25(7):873-84.

119.JiangY,RigogliosoA,PeterhoffCM,PawlikM,SatoY,BleiwasC,StavridesP,SmileyJF,GinsbergSD,MathewsPM, Levy E, Nixon RA. Partial BACE1 reduction in a Down syndrome mouse model blocksAlzheimer-relatedendosomalanomaliesandcholinergicneurodegeneration:roleofAPP-CTFNeurobiolAging2016;39:90-8.

120.SarkoDK,McKinneyCE.Exosome:Originsand therapeuticpotential forneurodegenerativediseaseFrontiersneurosci2017;Feb27;11:82.

121.GauthierSA,McKinneyCEEnhancedexosomesecretioninDownsyndromebrain:aprotectivemechanismtoalleviateneuronalendosomalabnormalitiesActaNeuropathologicaCommunications2017;5:65.

122.HamlettED,LedreuxA,PotterH,ChialHJ,PattersonD,EspinosaJM,BettcherBM,GranholmACExosomalbiomarkersinDownsyndromeandAlzheimer’sdiseaseFreeRadicBiolMed.2018Jan;114:110-121;doi:10.1016/j.freeradbiomed.2017.08.028.Epub2017Sep5.Review.

123.SanseveroG,BegenisicT,MainardiM,SaleA.Experience-dependentreductionofsolubleβ-amyloidoligomersandrescueofcognitiveabilitiesinmiddle-ageTs65Dnmice,amodelofDownsyndrome.ExpNeurol2016;283(PtA):49-56.

124. PavelV,MadaniR,Rey-Bellet L, PihlgrenM,BeckerA, PlassardA,Vuillermot S,GiriensV,NoshenyRL,KleschevnikovAM,VallettaJS,BengtssonSK,LinkeGR,MaloneyMT,HickmanDT,ReisP,GranetA,MlakiD,Lopez-DeberMP,DoL,SinghalN,MasliahE,PearnML,PfeiferA,MuhsA,MobleyWC.AnAnti-β-AmyloidVaccineforTreatingCognitiveDeficitsinaMouseModelofDownSyndromePLoSOne2016;11(3):e0152471.

26


125. Gueroux M Fleau C, Slozeck M, Laguerre M, Pianet I Epigallocatechin 3-Gallate as an Inhibitor of TauPhosphorylationandAggregation:AMolecularandStructuralInsight.JPrevAlzheimersDis2017;4(4):218-225.

126.XicotaL,Rodriguez-MoratoJ,DierssenM,delaTorreRPotentialRoleof(-)-Epigallocatechin-3-Gallate(EGCG)intheSecondaryPreventionofAlzheimerDisease.CurrDrugTargets2017;18(2):174-195.

127.Catuara-SolarzS,Espinosa-Carrasco J,Erb I,LangohrK,Gonzalez JR,NotredameC,DierssenMCombinedTreatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits andHippocampalAlterationsinaMouseModelofDownSyndromeeNeuro2016;3(5):0103-16.2016.

128.NeumannF,GourdainS,AlbacC,DekkerAD,BuiLC,DairouJ,Schmitz-AfonsoI,HueN,Rodrigues-LimaF,DelabarJM,PotierMC,LeCaërJP,TouboulD,DelatourB,CariouK,DoddRH.DYRK1Ainhibitionandcognitiverescue in aDown syndromemousemodel are inducedbynewfluoro-DANDYderivativesSciRep2018; 8: 2859.Publishedonline2018Feb12.

129.NguyenTLDuchonA,AntigoniManousopoulouA,etalCorrectionofcognitivedeficitsinmousemodelsofDownsyndromebyapharmacologicalinhibitorofDYRK1ADisModelMech.2018;11(9):dmm035634.

130.ChangCYTingHC,LiuCA,SuHL,ChiouTW,HarnHJ,LinSZ,InducedPluripotentStemCells:APowerfulNeurodegenerativeDiseaseModelingToolforMechanismStudyandDrugDiscoveryCellTransplant2018;27(11):1588–1602.

131.Nakano-KobayashiaA,AwayaT,KiiI,SumidaY,OkunoY,YoshidaS,SumidaT,InoueH,HosoyaT,HagiwaraM.PrenatalneurogenesisinductiontherapynormalizesbrainstructureandfunctioninDownsyndromemice.PNAS2017;114,3810268-10273.

132. Dashinimaev EBArtyuhovAS, BolshakovAP, Vorotelyak EA, VasilievAV Neurons Derived from InducedPluripotentStemCellsofPatientswithDownSyndromeReproduceEarlyStagesofAlzheimer’sDiseaseTypePathologyin vitro.JAlzheimersDis2017;56(2):835-847.

Download - Alzheimer’s Disease & Treatment - Open Access eBooksopenaccessebooks.com/alzheimers-disease-treatment/down... · 2019. 3. 15. · Alzheimer’s Disease & Treatment London J nuclei

Top Related